Aryl lactam kinase inhibitors

US8901305B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Vivekananda M. Vrudhula · Killingworth, US
• Senliang Pan · Woodbridge, US
• Ramkumar Rajamani · Wallingford, US
• Susheel Jethanand Nara · Mumbai, IN
• Maheswaran Sivasamban Karatholuvhu · Chennai, IN
• Tarun Kumar Maishal · Bengaluru, IN
• Jonathan L. Ditta · Meriden, US
• Carolyn Diane Dzierba · Middletown, US
• Joanne J. Bronson · Madison, US
• John E. Macor · Guilford, US

Key dates

• Filing date: Jul 19, 2013
• Grant date: Dec 2, 2014
• Expiry date: Jul 19, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.